Following on from information provided to NICE by the company in September 2020 the appraisal of Niraparib for previously treated hormone-relapsed metastatic prostate cancer with DNA-repair anomalies [ID3782] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 3782 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 21 December 2022 | Discontinued. Following on from information provided to NICE by the company in September 2020 the appraisal of Niraparib for previously treated hormone-relapsed metastatic prostate cancer with DNA-repair anomalies [ID3782] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 15 September 2020 | Suspended. Topic is suspended |
| 15 September 2020 | The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of niraparib for previously treated hormone-relapsed metastatic prostate cancer with DNA-repair anomalies. For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the European Medicines Agency for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes. |
| 01 April 2020 | Topic has been proposed |
For further information on our processes and methods, please see our CHTE processes and methods manual